Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a Sugar-Tracking scan predict cancer treatment success?

NCT ID NCT01996046

Diagnosis Sponsor: University of Pennsylvania Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study looks at whether a special type of PET/CT scan (called FDG PET/CT) can help doctors see how well hormone therapy is working in breast cancer that has spread to the bones. About 75 adults with estrogen receptor-positive breast cancer and bone metastases will get the scan before starting a new hormone treatment, then again at 4 weeks and 12 weeks after. The goal is to see if changes in the scan can predict how long the cancer stays under control and overall survival.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
FDG PET/CT scan (a special imaging test using a radioactive sugar tracer)
What this could lead to
If successful, this could help doctors use PET/CT scans to more accurately predict how well hormone therapy is working in breast cancer that has spread to bones.
What could go wrong
This is an early-stage imaging study with only 75 participants, so results may not apply to all patients. The scan's ability to predict long-term outcomes is still unproven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 75 people

The number the study aims to enrol. It can still change while the study runs.

Start date

Sep 2013

Expected to finish

Jul 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients with a history of ER+ breast cancer with documented bone metastases from breast cancer. Patients must be planning to start new hormone therapy for their breast cancer.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Adult patients, at least 18 years of age, with a history of pathologically confirmed ER+ breast cancer 2. Biopsy proven or clinically obvious documented bone metastases from breast cancer (with the majority of the disease burden in the bone) 3. Patients planning to start new endocrine targeted therapy (any line of therapy is acceptable and any endocrine therapy is allowed) 4. Willing and able to comply with scheduled visits and serial imaging procedures 5. Agrees to allow access to clinical records regarding response to treatment and long term follow up. 6. Be informed of the investigational nature of this study and provide written informed consent in accordance with institutional and federal guidelines Exclusion Criteria: 1. Women who are pregnant or breast feeding 2. Uncontrolled diabetes mellitus (fasting glucose greater than 200 mg/dL) 3. Inability to tolerate imaging procedures (e.g. claustrophobia, severe pain) 4. Weight exceeding capacity of imaging table 5. Previous treatment with radiation or surgery to a significant percentage of bony metastatic sites 6. Treatment with marrow stimulating agents (e.g. granulocyte colony stimulating factor (GCSF)) within 3 weeks of baseline scan

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bone metastases are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

estrogen-receptor positive breast cancer metastatic carcinoma in the bone

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Bone metastases Estrogen-receptor-positive breast cancer

Contacts and locations

Locations

  • University of Pennsylvania Hospital

    Philadelphia, Pennsylvania, 19104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.